YehKcBeyerEtBreaultGoLeiBW.Effect of sustained release on the pharmacokinetic profile of indomethacin in man. Biopharm Drug Dispos1982; 3: 219–30.
2.
VerbesseltR.TjandramagaTbMullieA.Comparative multiple dose kinetics of two formulations of indomethacin. Eur J Clin Pharmacol1983; 24: 563–8.
3.
BrashArHickeyDeGrahamTpStahlmanMtOatesJaCottonRB.Pharmacokinetics of indomethacin in the neonate. N Engl J Med1981; 305: 67–72.
4.
VertP.BianchettiG.MarchalF.MoninP.MorselliPL.Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol1980; 18: 83–8.
5.
HoltLPJHawkinsCF.Indomethacin: studies of absorption and the use of indomethacin suppositories. Br Med J1965; 1: 1354–6.
6.
VignonE.ChapuyMC.Bioavailability of indomethacin: study of a sustained release preparation. Rev Rheum Mal Osteoartic1979; 56: 505–8.
7.
FashingU.EberlR.Comparison of a new sustained action formulation of indomethacin with conventional indomethacin. Wien Med Wochenschr1978; 128: 733–6.
8.
GengosDcNeuDcMiolaSR.Evaluation of sustained release indomethacin in osteoarthritis. Semin Arthritis Rheum1982; 12: 142–6.
9.
HartCbRhymerArMiolaSrIndocinSr (Indomethacin MSD) in the treatment of moderate to severe rheumatoid arthritis. Semin Arthritis Rheum1982; 12: 147–51.
10.
SchoogM.LaufenH.DessainP.A comparison of the pharmacokinetics of piroxicam with those of plain and slow release indomethacin. Eur J Rheumatol Inflamm1981; 4: 298–302.
